Tebotelimab

Names

[ CAS No. ]:
2245725-04-4

[ Name ]:
Tebotelimab

Biological Activity

[Description]:

Tebotelimab (MGD-013) is a human IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity[1][2][3].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1
Research Areas >> Inflammation/Immunology

[In Vitro]

MGD013 (0.39, 1.56, 6.25, 25 nM; 48 小时) 增强人 PBMC 中 T 细胞抗原受体驱动的激活。与 PD-1 + LAG-3 mAb 组合相比，MGD013 显示增强的葡萄球菌肠毒素 B (SEB; 0.5mg/mL) 诱导 IFN-γ 分泌[1]。

[References]

[1]. Ross LaMotte-Mohs, et al. Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment. Cancer Res (2016) 76 (14_Supplement): 3217.

[2]. Daniel Vt Catenacci, et al.MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol. 2021 Apr;17(10):1155-1164.  

[3]. Yiming Wei, et al. LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance. Front Oncol. 2022 Apr 14;12:831407.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.